DE602007011123D1 - Verfahren zur Herstellung eines Krebsimpfstoffs - Google Patents

Verfahren zur Herstellung eines Krebsimpfstoffs

Info

Publication number
DE602007011123D1
DE602007011123D1 DE602007011123T DE602007011123T DE602007011123D1 DE 602007011123 D1 DE602007011123 D1 DE 602007011123D1 DE 602007011123 T DE602007011123 T DE 602007011123T DE 602007011123 T DE602007011123 T DE 602007011123T DE 602007011123 D1 DE602007011123 D1 DE 602007011123D1
Authority
DE
Germany
Prior art keywords
dendritic cells
producing
cancer
tumour cell
cancer vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007011123T
Other languages
English (en)
Inventor
Tan Sri Datuk Yusof Dr Basiron
Hafid Sitti Rahma Abdul
Kanga Rani Selvaduray
Kalanithi Dr Nesaretnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palm Oil Research and Development Board
Original Assignee
Palm Oil Research and Development Board
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palm Oil Research and Development Board filed Critical Palm Oil Research and Development Board
Publication of DE602007011123D1 publication Critical patent/DE602007011123D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602007011123T 2006-02-03 2007-02-02 Verfahren zur Herstellung eines Krebsimpfstoffs Active DE602007011123D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20060439A MY160857A (en) 2006-02-03 2006-02-03 A cancer vaccine

Publications (1)

Publication Number Publication Date
DE602007011123D1 true DE602007011123D1 (de) 2011-01-27

Family

ID=38057880

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007011123T Active DE602007011123D1 (de) 2006-02-03 2007-02-02 Verfahren zur Herstellung eines Krebsimpfstoffs

Country Status (6)

Country Link
US (1) US7776324B2 (de)
EP (1) EP1815856B1 (de)
JP (1) JP5303113B2 (de)
AT (1) ATE491448T1 (de)
DE (1) DE602007011123D1 (de)
MY (1) MY160857A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148321A (en) * 2007-10-02 2013-03-29 Malaysian Palm Oil Board Mpob Vitamin e supplementation to tetanus toxoid
CN105288602A (zh) * 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
CN110885788B (zh) * 2019-12-13 2021-08-17 北京和合医学诊断技术股份有限公司 人肠癌原代细胞、应用和培养方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458585B1 (en) * 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
HUP0300772A3 (en) 2000-07-28 2005-11-28 Liponova Ag Medicament for the immunotherapy of malignant tumours
DE60232895D1 (de) * 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
WO2004050855A2 (en) * 2002-12-04 2004-06-17 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
EP1885353B1 (de) * 2005-04-22 2015-01-07 Elizabeth Stuart Verwendung von vitamin-e-tocotrienolen zur inhibierung des intrazellulär obligaten pathogens chlamydia

Also Published As

Publication number Publication date
JP5303113B2 (ja) 2013-10-02
US7776324B2 (en) 2010-08-17
US20070231351A1 (en) 2007-10-04
ATE491448T1 (de) 2011-01-15
EP1815856B1 (de) 2010-12-15
MY160857A (en) 2017-03-31
EP1815856A3 (de) 2008-05-07
EP1815856A2 (de) 2007-08-08
JP2007254458A (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
ATE455463T1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
AU2008298744A8 (en) MiRNA expression in human peripheral blood microvesicles and uses thereof
NO20092522L (no) Sammensetninger og fremgangsmater for a behandle kreft med cupredoxiner og CPG rikt DNA
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BRPI0921726B8 (pt) método para preparar uma composição de implante para promover o crescimento ósseo em um mamífero
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BRPI0814330B8 (pt) métodos e kits cirúrgicos
WO2008039874A3 (en) Cancer stem cell antigen vaccines and methods
EA200802213A1 (ru) Способы лечения заболеваний крови
WO2009151907A3 (en) Compositions and methods for using cells to treat heart tissue
NO20090598L (no) 6,9-disubstituerte purinderivater og deres anvendelse for behandling av hud
WO2010091049A3 (en) Diagnosis and treatment of cancer
IN2014MN01981A (de)
CL2008002089A1 (es) Compuesto para la regeneracion de tejidos que comprende al menos una sustancia derivada de sangre y acido hialuronico y/o al menos un compuesto derivado de acido hialuronico; metodo para la prepararcion de dicho compuesto.
EP2560002A3 (de) Verfahren zum Isolieren und/oder Identifizieren mesenchymaler Stammzellen
EA201001749A1 (ru) Способ лечения недифференцированного артрита
MX2010005863A (es) Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.
BRPI0815460A2 (pt) kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos
WO2006093860A3 (en) Method and composition for repairing heart tissue
ATE491448T1 (de) Verfahren zur herstellung eines krebsimpfstoffs
EA201290107A1 (ru) Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии
WO2007137827A8 (de) Isoliertes naturidentisches kollagen
ATE552866T1 (de) Verfahren zur herstellung eines azellulären organischen gewebes
ATE487730T1 (de) Verfahren zur herstellung eines oxaliplatins
MX2007008441A (es) Metodo para producir una vacuna para el tratamiento de cancer.